Theralase Technologies Inc. V.TLT

RE:RE:RuBCG HUGE POTENTIAL

[CancerSlayer]

CancerSlayer wrote:

Tarbaby wrote: Their discovery that Rudivar combined with BCG increased the effectivness of BCG is potentially a huge game changer for bladder cancer treatment.
That alone might be worth billions..
They have so many cookies in their cookie jar..

Yep...you can now add RuBCG to their list of invaluable "proprietary" formulations.  The in-vitro data suggests RuBCG has the potential to replace BCG as the stand-alone therapy/standard of care for NMIBC imo.  The beauty of its potential is found in its mechanism of action (MOA).   It turns a negatively-charged BCG, which is repelling to a negatively-charged cancer cell surface, into a positively-charged compound, making attachment & uptake into a cancer cell more efficient.  

It was also noted in the in-vitro study that RuBCG decreased the number of PD-L1 checkpoint proteins on the cancer cell surface, thereby increasing its immunogenicity & cell kill (the latter by almost 200% per the graph presented in the NR) vs either compound alone...& that's non-light activated.  

There's huge potential imo for RuBCG to not only replace BCG, but to also potentially simplify (reduce treatments) & minimize toxicity of the current SOC for NMIBC (BCG).  JMO.

Additionally, Rutherrin was also found to decrease the expression of PD-L1 proteins on NMIBC & GBM cancer cells, thereby allowing a better immune response & higher cancer cell kill rate.  This MOA can potentially be utilized in combination with other approved PD-L1 inhibitors (i.e. Durvalumab, Atezolizumab) in order to make these inhibitors become more effective/efficient.  You get a true one-two punch when considering Rutherrins' direct cell kill + its indirect cell kill via enhancement of the immune response.   

If there's any barrier to IP-based funding, it would be trying to place a value on this company's growing IP ; ).  I can't see it being worth less than tens of millions at this stage of development.  All imo...